All News

Study finds the number of patients who are eligible for and may respond to checkpoint inhibitor therapies is higher than for genome-driven therapies.

Eighty-three percent of physicians excising more-than-necessary amounts of tissue on a regular basis during Mohs micrographic surgery.

Lawmakers said the generic and biosimilar manufacturers depend on the 2 databases to bring more affordable medications to the market.

Top news of the day from across the health care landscape.

According to Sandoz, the company is working to make its epinephrine 0.3 mg and 0.15 injections available to the retail market, which would enable individuals to obtain this medicine at local pharmacies.

In announcing the requirement, Health and Human Services Secretary Alex Azar said Americans deserve to know the prices of the medications they receive.

Positive results were collected from a Phase 3 study of an investigational fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis (SAR), according to Glenmark Pharmaceuticals.

Premier Inc. announced on Tuesday it is selling its specialty pharmacy business to ProCare Pharmacy LLC, a subsidiary of CVS Health Corporation.

There is no cure for multiple sclerosis, but there are more than a dozen treatment options that aid in reducing the severity of the disease.

The national retail chain is also providing a more wholesome assortment of pet foods and the company is expanding in-store veterinary clinics.

Treatment with tagraxofusp yielded high response rates in patients with blastic plasmacytoid dendritic cell neoplasm.

Top news of the day from across the health care landscape.

Suzanne Soliman, PharmD, founded the Pharmacist Mom Group on Facebook, and it has since grown to be 1 of the most active on the popular social media platform, with more than 2 million posts last year alone.

A study in 2008 showed that approximately 5.2% of US adults age 18-80 years used benzodiazepines.

Using genetic testing for women newly diagnosed with breast cancer can decrease the high cost of chemotherapy use in the first year of care.

Top news of the day from across the health care landscape.

Although the prevalence of LEMS in children is not known, the overall prevalence is estimated to be 3 per million individuals worldwide, according to the FDA.

Amifampridine (Ruzurgi, Jacobus) is the first treatment approved specifically for pediatric patients 6 to 17 years of age with Lambert-Eaton myasthenic syndrome.

When applying for the grant for Realo Discount Drug’s Transition to Wellness Program, Christina Nunemacher's goal was to show that involving pharmacists in the hospital discharge process could lower readmission rates.

A certain type of DNA rearrangement that is rarely tested for may be a predictor of prognosis in multiple myeloma.

Ado-trastuzumab emtansine (Kadcyla) is currently the only antibody-drug conjugate approved for the treatment of HER2-positive early and metastatic breast cancer.

Prior to this approval, there were no available treatments for ATTR-CM, only symptom management and, in rare cases, heart transplant.

Top news of the day from across the health care landscape.

How did a man with low sperm county get his wife pregnant?

Dapagliflozin is a selective sodium‑glucose cotransporter-2 (SGLT-2) inhibitor that is combined with a dipeptidyl peptidase‑4 (DPP‑4) inhibitor, saxagliptin; and metformin hydrochloride extended release.

Transthyretin amyloid cardiomyopathy is a rare and fatal disease for which there are no previously approved treatments.

Can omega 3 oils calm inflamation?

Pivotal phase 3 trial results show benefits for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy Ellipta) in patients with uncontrolled asthma compared with standard FF/VI (Breo Ellipta) therapy.

In the first and largest study of its kind, researchers from the University of British Columbia (UBC) and Vancouver Coastal Health Research Institute aimed to assess mortality associated with beta interferons for the treatment of MS.

The FDA rapidly reviewed and approved Genentech’s application under the FDA’s Real-Time Oncology Review (RTOR) and Assessment Aid pilot programs, leading to an approval 12 weeks after completing the submission.